Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03224598
Recruitment Status : Completed
First Posted : July 21, 2017
Results First Posted : February 10, 2020
Last Update Posted : March 30, 2020
Sponsor:
Information provided by (Responsible Party):
Aclaris Therapeutics, Inc.

Brief Summary:
Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.

Condition or disease Intervention/treatment Phase
Dermatosis Papulosa Nigra Drug: A-101 Topical Solution 40% Phase 2

Detailed Description:

The main objective of this study is to evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.

The secondary objectives of this study include:

  • Durability of response
  • Safety

An exploratory objective of this study will evaluate the subject's assessment of the treatment of A-101 to DPN lesions using a Subject Self-Assessment Scale.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

The first cohort of the study will enroll a total of 12 subjects. In the second part of the study, subjects will be a randomized to additional two-arm cohorts. Subjects will be randomized to one of the following 2 treatment arms:

  • A-101 40% without medically abrading the identified DPN prior to treatment
  • A-101 40% with the identified DPN lesions medically abraded prior to treatment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Open Label Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
Actual Study Start Date : June 26, 2017
Actual Primary Completion Date : January 8, 2019
Actual Study Completion Date : January 8, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Skin Conditions

Arm Intervention/treatment
Experimental: No medical abrading
A-101 40% without medically abrading the identified DPN prior to treatment
Drug: A-101 Topical Solution 40%
A-101 Topical Solution 40%

Experimental: Medically abrading
A-101 40% with the identified DPN lesions medically abraded prior to treatment
Drug: A-101 Topical Solution 40%
A-101 Topical Solution 40%

Experimental: Initial cohort - no medical abrading
A-101 40% without medically abrading the identified DPN prior to treatment
Drug: A-101 Topical Solution 40%
A-101 Topical Solution 40%




Primary Outcome Measures :
  1. Physician's DPN Lesions Assessment [ Time Frame: Day 106 ]

    Efficacy endpoints will include summary statistics (frequency distributions, proportions, means, medians and standard deviations, as appropriate) by visit for the following parameters: Physician's DPN Lesion Assessment scale results per treated lesion, subject responders defined by Physician's DPN Lesion Assessment scale outcome, and changes from baseline treated lesion diameter

    Physician's DPN Lesion Assessment Grade Descriptor 0 Clear: no visible DPN lesion;

    1. Near Clear: a slightly visible DPN lesion; lesion may be macular
    2. Small: a visible DPN lesion with a diameter of less than 3 mm
    3. Large : a visible DPN lesion that is elevated with a diameter of ≥3 mm



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provisions of written informed consent for participation in this study.
  2. Male or female ≥ 18 years old.
  3. Subject has a clinical diagnosis of dermatosis papulose nigra.
  4. Fitzpatrick Skin Type of 5 or 6
  5. Subject has 4 target DPN lesions located in an area that has not been previously treated.
  6. Subject chemistry and complete blood count results are within normal limits for the central laboratory.
  7. Woman of childbearing potential must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of birth control for the duration of the study
  8. Subject is non-pregnant and non-lactating.
  9. Subject is in good general health and free of any known disease state or physical condition.
  10. Subject is willing and able to follow all study instructions and to attend all study visits.

Exclusion Criteria:

  1. Subject has clinically atypical and /or rapidly growing DPN lesion.
  2. Subject has current systemic malignancy.
  3. Subject has a history of keloids
  4. Subject has a history of post inflammatory hyperpigmentation lasting longer than 1 year.
  5. Subject has used any of the following systemic therapies within the specified period prior to Visit 1:

    • Retinoids; 180 days
    • Corticosteroids; 28 days
    • Antimetabolites (e.g., methotrexate); 28 days
  6. Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to any Target Lesion, that in the investigator's opinion interferes with the study medication treatment or the study assessments:

    • LASER, light or other energy based therapy (e.g., intense pulsed light [IPL], photo-dynamic therapy [PDT]; 180 days
    • Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-fluoruracil (5FU), or ingenol mebutate; 60 days
    • Retinoids; 28 days
    • Microdermabrasion or superficial chemical peels; 14 days
    • Corticosteroids or antibiotics; 14 days.
  7. Subject currently has or has had any of the following within the specified period prior to Visit 1 on or in a proximity to any Target Lesion that, in the investigator's opinion, interferes with the study medication treatment or the study assessments:

    • Cutaneous malignancy; 180 days
    • Sunburn; currently
    • Pre-malignancy (e.g. actinic keratosis); currently
    • Body art (e.g. tattoos, piercing, etc.); currently
    • Excessive tan. The use of self-tanning lotions/sprays are prohibited.
  8. Subject has a history of sensitivity to any of the ingredients in the study medications.
  9. Subject has any current skin disease (e.g. psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g. sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations.
  10. Participation in another therapeutic investigational drug trial in which administration of an investigational study medication occurred with 30 days prior to Visit 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03224598


Locations
Layout table for location information
United States, District of Columbia
Aclaris Investigational Site
Washington, District of Columbia, United States, 20037
United States, New York
Aclaris Investigational Site
New York, New York, United States, 10155
Sponsors and Collaborators
Aclaris Therapeutics, Inc.
  Study Documents (Full-Text)

Documents provided by Aclaris Therapeutics, Inc.:
Study Protocol  [PDF] March 28, 2018
Statistical Analysis Plan  [PDF] February 19, 2019


Layout table for additonal information
Responsible Party: Aclaris Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03224598    
Other Study ID Numbers: A-101-DPN-201
First Posted: July 21, 2017    Key Record Dates
Results First Posted: February 10, 2020
Last Update Posted: March 30, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Skin Diseases, Papulosquamous